Clinical trial

Effect of Efpeglenatide on Cardiovascular Outcomes

NCT03496298

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2018-04-27

PhasePHASE3

Study timeline

Study start (actual)2018-04-27Date precision: day

Registry last updated2021-10-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

Efpeglenatide (SAR439977)DRUG

PlaceboDRUG

Sponsors & collaborators

Sanofilead sponsor

Hanmi Pharmaceutical Company Limitedcollaborator

Mapped research locations

SantiagoChile9 SeoulSouth Korea7 Saint PetersburgRussia6 LimaPeru6 BudapestHungary5 MoscowRussia4 BelgradeSerbia4 JacksonvilleFlorida, United States3 SofiaBulgaria3 MonterreyMexico3 GuadalajaraMexico3 HoustonTexas, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03496298 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.